News

Professor Ilja Arts, scientific director of the Maastricht Centre for Systems Biology (MaCSBio), announced at the first MaCSBio Science day on 17 May that the institute would focus on two research lines: systems medicine of chronic diseases and computational and systems neuroscience.

Chris Evelo (ELIXIR Netherlands) is the new co-leader of the ELIXIR Interoperability Platform, replacing Barend Mons, the Head of Dutch ELIXIR Node. Evelo joins Helen Parkinson (EMBL-EBI) and Carole Goble (ELIXIR UK) in leading the Interoperability Platform.

MaCSBio's director of education Bert Smeets has been interviewed for the Dutch serie: 'Research Loont' (translation: 'Research pays off') about the unraveling of genetic causes of hereditary metabolic disease among children.

Neurogenesis is the process by which new neurons are generated from neural stem cells and progenitor cells which takes place continuously throughout our life. In this work the interdisciplinary team with Gökhan Ertaylan of MaCSBio has been collaborating, uncovers a function for Prox1 gene that...

Michelle Moerel from MaCSBio has been on the most famous educational tv-show for kids in The Netherlands ( Het Klokhuis ) to explain how the human brain works.

PhD-candidate Shauna O’Donovan has won a prize for best poster at the byteMAL Conference held on March 9th in Maastricht. Her poster subject was on improving the muscle insulin sensitivity index using the oral glucose minimal model.

Theo de Kok will give his Inaugural Lecture, entitled “Genes in Concert: a Toxicogenomics Hymn towards disease prevention” on Friday 22 April 2016. The lecture will take place at the University Auditorium - MBB. Time: 16:30

MaCSBio’s Mike Gerards was involved as a senior author in an article entitled “Novel pathogenic SLC25A46 splice-site mutation causes an optic atrophy spectrum disorder.” which was published in “Clinical Genetics”.

Maastricht University participates in two new Horizon 2020 projects in the field of Data Science and Knowledge Engineering.

This year, the buildings 1 & 4 will be prepared for accommodating startup companies and AMIBM (Aachen-Maastricht Institute for Biobased Materials). The current users (DSM ACES and DBIS) have already moved to other offices and facilities (or they will shortly) and a major renovation of these...